Fresh success for Incyte's eczema trial program

19 February 2020
incytebig

A second Phase III study from Incyte’s (Nasdaq: INCY) TRuE-AD clinical trial program in mild-to-moderate atopic dermatitis (AD) has met its primary endpoint.

Following on from the positive top-line results from TRuE-AD2, the results of TRuE-AD1 also show that significantly more patients treated with ruxolitinib (trade name Jakafi) cream 0.75% or 1.5% achieved investigator’s global assessment treatment success.

Almost 1,250 patients enrolled

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology